First Report Managed Care

Don’t miss tomorrow’s live webinar! Join Dr Saad Ashraf as he discusses how nerandomilast, the first new idiopathic pulmonary fibrosis (IPF) therapy in over a decade, is transforming care and access. Free to register >>> hubs.ly/Q03X7jmr0

Innovation in pulmonary fibrosis demands more than strategy. Hear from Dr Saad Ashraf on Monday, December 8 at 1 PM EST as he discusses how nerandomilast is redefining treatment and setting the stage for broader pulmonary fibrosis management. Register >>> hubs.ly/Q03WSQhz0

How is new evidence changing pulmonary fibrosis care? Join Dr Saad Ashraf on Monday, December 8 at 1 PM EST for an expert discussion on nerandomilast and how it is shaping treatment decisions. Register for Free >>> hubs.ly/Q03WxVdw0

Innovation in pulmonary fibrosis demands more than strategy. Hear from Dr Saad Ashraf on Monday, December 8 at 1 PM EST as he discusses how nerandomilast is redefining treatment and setting the stage for broader pulmonary fibrosis management. Register >>> hubs.ly/Q03WfVnj0

We’re going live tomorrow at 12:00 PM ET for our upcoming webinar From Innovation to Implementation: Rethinking Access in Idiopathic Pulmonary Fibrosis—will you be joining us? Secure your spot here! → hubs.ly/Q03MBrtz0

Are you registered for the upcoming idiopathic pulmonary fibrosis webinar on October 30? Join Elizabeth Volkmann, MD, and Carole Tremonti, RN, MBA, to learn more about clinical innovation. hubs.ly/Q03MBkRd0

As new therapies for idiopathic pulmonary fibrosis (IPF) emerge, healthcare stakeholders must navigate the balance between innovation and evidence-based coverage decisions. Register for this IPF webinar today! hubs.ly/Q03MBfHm0

Study authors examined the safety and effectiveness of pitolisant in #patients with type I narcolepsy who did not tolerate or respond to previous treatments. buff.ly/3EJkOoL

There's still time to register for the managed care considerations webinar on Addressing the Burdens of Alzheimer's Disease. Check out the two dates and times below! buff.ly/3iprwsF

Researchers assessed potential factors driving differences in #disease burden between African American and White patients with multiple sclerosis. buff.ly/3GSLhDa

Patients with relapsing/remitting multiple sclerosis reported improvements in #medication satisfaction, fatigue, and other measures after switching from other therapies to a monoclonal antibody. buff.ly/3OJabXL

Happening soon! There's still time to register for today's webinar on managed care considerations for the treatment of tardive dyskinesia. Can't make it? Check out the other date below! buff.ly/3UzmQOt

In the second part of this roundtable, Edmund Pezalla, MD, MPH; Adam Kittai, MD; Farrukh Awan, MD; and Jeffrey Dunn, PharmD, MBA, discuss cost and access challenges for treating #patients with zanubrutinib. buff.ly/3EMxPQ2

#ICYMI There is still time to register for tomorrow's Managed Care Considerations webinar happening at 1 p.m. buff.ly/3GU1pUX

In addition to the #Economic burden of the disease, researchers also reported the humanistic burden associated with pediatric-onset multiple sclerosis. buff.ly/3i7Ri4B

Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by #PublicHealth plans, findings show. buff.ly/3EnZepB

Study authors examined comorbidities and potential extaneural manifestations associated with spinal muscular atrophy in treatment-naive patients. buff.ly/3UUUyP2

Researchers examined the impact of #medication and symptom control on real-world quality of life in patients with #narcolepsy during 5 years of follow-up. buff.ly/3A8rwTO

Study authors examined the efficacy and safety of a 24-week regimen of CTP-543 in #patients with chronic, moderate-to-severe alopecia areata. buff.ly/3NWcjv0

In this commentary, Steven McNeilly offers insight into a health system's approach to value-based #care including advice for improving metrics and relationships with payers and providers. buff.ly/3E5glgY